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Abstract  
Due to the increasing occurrence of renal cell carcinoma (RCC) in the general 
population and the high prevalence of chronic kidney disease among cancer patients, 
many people with a previous RCC are considered as potential candidates for renal 
transplantation. They should accordingly be evaluated to assess their life expectancy 
and the risk that the chronic immunosuppressive therapy needed after grafting might 
impair their long-term outcome.  
Current guidelines on listing patients for renal transplantation suggest that no 
delay is required for subjects with small or incidentally discovered RCC, while the 
recommendations for patients who have been treated for a symptomatic RCC or for 
those with large or invasive tumours are conflicting.   
The controversial results reported by even recent studies focussing on the cancer 
risk in kidney graft recipients with a prior history of malignancy do not help to 
clarify the doubts arising in everyday clinical practice.  
Several tools, including integrated scoring systems, are currently available to 
assess the prognosis of patients with a previous RCC and, although they have not 
been validated in subjects receiving long-term immunosuppressive drugs, they can 
be used to identify patients suitable to be listed for grafting. Among these, the 
Leibovich score is currently the most widely used as it has proved simple and 
reliable enough and helps categorize renal transplant candidates. According to this 
system, subjects with a score from 0 to 2 are at low risk and may be listed without 
delay, while those with a score of 6 or higher should be excluded from grafting. In 
addition, other factors have an established positive prognostic value, including 
cromophobe or clear cell papillary tumour, or G1 grade cancer, while medullary or 
Bellini’s duct carcinoma or those with sarcomatoid dedifferentiation at histological 
examination should be excluded.  
Pending studies specifically focussing on cancer risk evaluation in people already 
treated for malignancy receiving long-term immunosuppressive therapy, all other 
patients had better be submitted to careful individual evaluation by an Oncologist 
and Urologist before being listed for renal transplantation.  
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Introduction 
The incidence of renal cell carcinoma (RCC) in the general population has 
progressively increased in the last few years and at present it accounts for 
approximately 2% to 3% of all adult malignancies, being the seventh most common 
cancer in men and the ninth most common cancer in women [1].  
According to The American Urological Association guidelines [2] as well as the 
European Association of Urology (EAU) guidelines [3], nephron-sparing surgery is 
at present the standard of care for T1a and most T1b lesions (i.e. lesions confined to 
the kidney that are no larger than 4 cm or 7 cm, respectively), with an A and B grade 
of recommendation, respectively, while in elderly and/or comorbid patients with 
small renal masses and limited life expectancy, active surveillance, radiofrequency 
ablation and cryotherapy can be considered (grade C) [3, 4]. Radical nephrectomy is 
the preferred option for T2 tumours, exceeding 7 cm, and for locally advanced (T3 
and T4) lesions (grade B).  
Given the high prevalence of chronic kidney disease among cancer patients [5], 
and as a result of surgery, some patients require dialysis treatment and, if they have 
no comorbid conditions, might be considered for transplantation listing, provided 
the cancer has been cured.  
However, considering that transplanted patients inherently have an increased risk 
of cancer when compared with the general population, mainly due to prolonged 
immunosuppressive therapy [6], they should be evaluated carefully before listing, in 
order to avoid first of all the risk of worsening the patient prognosis instead of 
improving it, and secondly the use of a scarce resource, such as donated organs, for 
subjects with a limited life span.  
 
Current guidelines 
Several guidelines have already addressed this problem suggesting a minimum 
waiting period between successful treatment of malignancy and transplantation, 
pending the achievement of the highest possible likelihood of 5-year patient survival. 
Decision making will still need to be personalized, accounting for the features of 
previous malignancy in individual patients and their clinical conditions.  
listing previous RCC - pag. 4 
Most international guidelines draw their data from the seminal publications by 
Penn and collaborators [7]. These articles summarise the outcomes of subjects with 
a prior malignancy undergoing renal transplantation, as voluntarily submitted to the 
Cincinnati Tumour Transplant Registry. Thus, they do not include all patients 
undergoing transplantation with a history of prior malignancy. Despite its 
imperfections, it remains the most informative and essentially the only solid 
published series in the literature. The concept of waiting times post successful 
treatment of a malignancy and prior to transplantation is based on the observation 
that cancer recurrence becomes less likely with an increasing disease-free interval 
post-treatment. Penn reported 54% of recurrences in patients who received a graft 
within 2 years of treatment for malignancy, while 33% were documented in patients 
transplanted between 2 and 5 years, and only 13% among those treated more than 5 
years before grafting [7].  
Only one out of 72 patients with a previous incidentally found RCC showed 
cancer recurrence after transplantation and no recurrence was reported in patients 
transplanted more than 5 years after cancer treatment. On the contrary, among 222 
patients with symptomatic RCC the recurrence rate was 27%, and the large majority 
of patients with recurrence (93%) received a transplant less than 5 years after cancer 
removal. Moreover, recurrence of RCC after grafting was associated with increased 
mortality and 49 (80%) deaths occurred in 61 patients with recurrence.  
After these observations Penn suggested that a 2-year waiting period is 
unnecessary for patients with an incidentally discovered RCC unless the tumour is 
large or infiltrates the kidney capsule, while a 5-year recurrence-free interval is 
appropriate for patients with symptomatic RCCs exceeding 5 cm.  It is important to 
highlight that the presence of symptoms is often, but not always, related to the local 
extension of the neoplasm; a small mass could induce haematuria or not, depending 
on its position, central or peripheric. Thus, it is questionable that the extent of the 
waiting time should be determined by the presence or absence of symptoms. 
However, the KHA-CARI Guidelines suggest that the evaluation include TNM 
staging (Tumour, regional lymphNodes, distant Metastases) and a histological 
examination to identify lesions with a higher likelihood of recurrence [8]. 
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On the other hand, no delay in listing for transplantation patients with small, 
incidentally discovered tumours, is recommended by current guidelines [9–13] 
(table I). On the contrary, current guideline recommendations for patients who have 
been treated for a symptomatic RCC are variable, ranging from 2 to 5 years’ waiting 
time, since they apply to subjects with large or invasive tumours, which are 
considered a contraindication to renal transplantation by some guidelines but 
accepted by others (table I).  
  
 
Cancer risk in kidney transplanted patients with a prior history of 
malignancy 
 
Whether a previous renal cancer is a risk factor for patients undergoing kidney 
transplantation, thus increasing the risk of death through malignancy, is still a matter 
of discussion given the conflicting data hitherto reported, even when derived from 
studies involving a large number of subjects.  
Two large registry data analyses have examined the risk of malignancy in 
patients after renal transplantation [14, 15]. It is of interest that patients with a prior 
history of malignancy are at increased risk of developing a de novo malignancy after 
transplantation but this risk exceeds that of recurrence of the original malignancy. 
An analysis of the Australia and New Zealand Dialysis and Transplant registry 
(ANZDATA) [14] reported an unadjusted hazard ratio of 2.08 (1.54-2.8) and an 
adjusted hazard ratio of 1.4 (1.03-1.89) for de novo malignancy in patients with a 
prior history of cancer, as compared with those without prior malignancy. Similarly, 
on analysing data from the Organ Procurement and Transplantation Network 
(OPTN), Kauffman et al. reported a de novo malignancy incidence of 7.8% in 
subjects with a prior history of malignancy versus 2.8% in those without [15]. In the 
same study, the rate of recurrence of the original malignancy was 2.3%. Their data 
do not appear to be adjusted for recipient age.  
In regard to the recurrence of a previous cancer, a more recent study analysed 
21,415 patients transplanted in Australia and New Zealand between 1965 and 2012, 
where 651 (3%) had a history of cancer before transplantation [16]. Only 23 of them 
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(3.5%) developed cancer recurrence after transplantation; since 7 of these had a 
malignancy of the urinary tract and 3 died during follow-up, it would seem that 
patients with a cancer history before transplantation may not be at a greater risk of 
death. From investigations in a Swedish cohort of 10,448 patients transplanted with 
a solid organ between 1970 and 2008 [17], 416 of whom (4%) had a cancer history 
before grafting, kidney and urothelial cell cancer being the most common types of 
cancer (21.9%), it emerged that among 66 out of 416 who died of cancer during 
follow-up, 39 (9.4%) died of the same cancer type as diagnosed before 
transplantation. In this cohort,  multivariate analysis revealed a more than three-fold 
increased rate of dying for cancer compared with other transplanted patients. 
However, patients who suffered from kidney or urothelial cell cancer before 
transplantation proved to have a 5-fold increased relative risk of dying of cancer 
[17].  
On the other hand, a study carried out in 19,103 patients who received a kidney 
transplant in England between 2001 and 2012 reported that subjects with a pre-
transplant history of cancer had a significantly higher risk of dying from malignancy 
as compared with those who did not and, interestingly, in this sub-group of patients, 
over half of all malignancy-related deaths were renal in origin [18]. This study 
confirmed the finding of an earlier study in 164,078 first kidney transplant recipients 
registered in the United States Renal Data System between 1990 and 2004, namely 
that a prior cancer history is an independent risk factor for cancer-related death after 
transplantation [19].  
The controversial results of even recent studies definitely affect the waiting time 
suggested by different authors before listing a patient who has suffered from cancer.  
Dahle et al. analysed the Norwegian registry - where, in accordance with local 
policy, patients with a cancer history were listed 1 year on from cancer treatment - 
and failed to find a significant difference in overall survival between patients with or 
without a previous cancer, although cancer-related mortality was increased in the 
former group, particularly in the first 5 years after grafting [20]. Since they found no 
association between the waiting period and recurrent cancer mortality, they 
proposed shortening the waiting time currently suggested by the guidelines [20].  
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Similarly, Nguyen et al. investigated the outcome of patients with ESRD related 
to renal malignancy who received a graft reported in the United States Renal Data 
System (USRDS), and concluded that cancer-specific mortality was not affected by 
waiting-time duration, while the overall survival rate was better in patients with a 
shorter waiting time [21].  
Of course, discrepancies in the reported studies may be due to several factors, 
including previous modes of cancer treatment, accuracy in patient follow-up, 
investigation of cancer recurrence before listing, and the criteria adopted in listing 
patients for transplantation. All these biases are even more relevant when dealing 
with studies based on registry data or metanalyses. However, taken together, they 
underline the need for a more precise approach to the problem allowing for planning 
the waiting time before listing according to the clinical setting of individual patients.  
 
Criteria for listing patients with previous renal cancer 
The issue of listing for kidney transplantation subjects with previous RCC is far 
from a trivial problem, in view of the implicit question underlying: when should a 
cancer patient be considered cured? Or, in other words, are we able to precisely 
quantify the risk of relapse in a patient who has been radically operated on for a 
given tumour (in this case RCC)? 
This is further complicated by the fact that no specific data are available for 
transplanted patients on immunosuppressive therapy. 
So far, the decision has been based on current guidelines which are mainly 
derived from observations coming from the Cincinnati Registry, which essentially 
considers the type of tumour and the time elapsed between treatment and kidney 
transplantation as the main criteria. Certainly, there is not enough evidence to 
support a fixed waiting period before transplantation for these patients, and there is 
the need for a different approach to reach a more accurate evaluation of the risk of 
recurrence after transplantation in individual patients. 
However, when restricting our quest to kidney cancer some useful tools are 
currently available to help us decide, including histological features and new staging 
systems, briefly reviewed below. 
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TNM (Tumour, regional lymphNodes, distant Metastases) staging 
Correct tumour staging – using the latest version [22] of the widely applied and 
easy to use TNM system – is the first tool to predict the risk of recurrence in a 
patient treated with radical nephrectomy for a kidney tumour. According to the 
SATURN project [23], which analysed more than 5,000 cases of kidney cancer who 
underwent surgery during the period between 1997 and 2007 in 16 Italian Centres, 
the probability of survival at 5 years is inversely related to tumour size: it was 
respectively 94.9% in the case of pT1a tumours, 92.6% in pT1b tumours, 85.4% in 
pT2a tumours, 70% in pT2b tumours, 64.7% in pT3a tumours, 54.7% in pT3b 
tumours, 17.9% in pT3c tumours, and finally 27.1% in pT4 tumours.  
Other parameters, not included in the TNM system, have been proposed over 
time to play a negative prognostic role, including the infiltration of the urinary tract 
and the infiltration of the kidney sinus [24]. As expected, the spread of the tumour to 
regional lymph nodes is associated with a significantly worse survival, as compared 
to organ-confined disease, as again demonstrated by the SATURN project data [23].  
Of course, metastatic kidney cancer patients have the worst prognosis and even 
though patients who are rendered metastasis-free by surgery are known to have a 
better prognosis (as compared to patients with in situ metastases), they should be 
regarded as incurable, and should not be considered for organ transplantation. 
Histology 
Histology is another important prognostic feature. Clear cell RCCs, by far the 
commonest histotype of kidney carcinoma, have a cause-specific survival 
significantly worse than papillary and chromophobe tumours; furthermore, among 
papillary renal cell carcinomas, type I is characterized by a slightly etter prognosis 
than type II. Finally, chromophobe carcinomas are considered to be particularly 
indolent, even though no significant differences in terms of prognosis have been 
reported compared to papillary tumours [25, 26]. 
As a whole, the percentage of cause-specific survival at 5 years varies between 
43% and 83% for clear cell carcinomas, between 61% and 90% for papillary 
carcinomas, and between 80% and 100% for chromophobe carcinomas [25]. This 
wide range of cause-specific survival suggests that histology should not be taken 
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into account as a single prognostic index for transplantation purposes, at least when 
only the three commonest histotypes are considered. Certainly, patients who have 
renal carcinomas with particularly poor prognosis such as medullary carcinomas or 
Bellini’s duct carcinomas should be excluded as both kidney donors and recipients, 
since their prognosis is dramatically dismal [27], even after a radical resection of a 
localized primary. 
 
Tumour grade 
Tumour grade is another pathological feature of kidney carcinomas which has 
proved to hold prognostic significance; however, its evaluation is closely dependent 
on the specific expertise of the pathologist who examines the histological specimens.  
Furthermore, following the 2013 Vancouver ISUP consensus conference, a 
simplified nucleolar grading system is now recommended and is being gradually 
implemented in everyday clinical practice [28]. This new grading system seems to 
reduce the inter-observer variability in pathological assessment.  
 
Sarcomatoid de-differentiation 
Sarcomatoid de-differentiation represents a transformation of the tumour towards 
a higher degree of malignancy [29]. On the morphological level, it is characterized 
by the presence of spindle or rhabdoid cells with ultrastructural and 
immunohistochemical evidence of epithelial and mesenchymal differentiation. This 
can be considered a common aspect, irrespective of the primary tumour histology, 
suggesting an increased biological aggressiveness. 
Literature results suggest that the presence of a framework of sarcomatoid de-
differentiation is generally associated with a median survival of approximately 12 
months and with a 5- and 10-year cause-specific survival of 22% and 13%, 
respectively [30]. In relation to the main tumour histologies, data from the Mayo 
Clinic show that 2 years after surgical treatment in patients with sarcomatoid 
differentiation, survival was 30%, 40% and 25% in patients with clear cell, papillary 
or chromophobe histology, respectively, whilst in patients without sarcomatoid de-
differentiation the figures were 84%, 96% and 96%, respectively [31]. 
Integrated prognostic systems 
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With a view to improving the prognostic accuracy of the individual clinico-
pathological factors considered, in recent years many authors have proposed the use 
of mathematical models based on integration of the major prognostic factors [32]. 
The two systems which are most widely utilized are probably the UCLA Integrated 
Staging System (UISS) [33] and the Leibovich score [34], which have also been 
utilized recently to stratify patients for clinical trials of adjuvant therapy [35]. 
The UISS [33] is able to predict the overall survival of patients with RCC 
according to the disease pathology stage (according to the 1997 TNM classification), 
Fuhrman’s nuclear grading and the Eastern Cooperative Oncology Group (ECOG) 
performance status. This system may be applied to kidney cancer patients with both 
localised and metastatic disease, and helps subdivide them into groups with low, 
intermediate and high risk of mortality. 
In patients with non-metastatic disease, application of the UISS can correctly predict 
the prognostic performance of these patients in a percentage ranging from 76.5% to 
86.3%. Notably, this system has been developed regardless of histology. 
In 2003, Leibovich et al. [34] developed another scoring system which proved to 
have higher than 80% predictive accuracy and enabled identification of three groups 
of patients with a different risk of developing metastasis: high, intermediate and low, 
respectively. This model has the advantage of taking into account the lack of lymph 
nodes at pathological evaluation of the surgical specimen (Nx status), an event 
which occurs with increasing frequency for several reasons, including the 
widespread use of mini-invasive surgical techniques [34]. 
In 2010 Klatte et al. [36] developed ad validated another prognostic nomogram 
specifically designed for papillary kidney carcinomas. This nomogram takes into 
consideration the following variables: incidental presentation of the tumour, T stage, 
M stage, presence of vascular invasion, and presence of necrosis. External 
independent validation revealed the 94.2% predictive accuracy of this nomogram. 
At present, however, no study has compared the different integrated prognostic 
systems available, with  a view to identifying the ideal one, if any. 
Even though no specific study has been carried out in immunosuppressed 
subjects, these tools could help in selecting potential kidney transplant recipients. 
Patients with a high probability of being disease- or metastasis-free at a given 
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timepoint could thus receive a kidney graft safely enough, whilst those at high risk 
of relapsing or of dying from the tumour should not be listed for transplantation, 
given the probability of a short survival.  
 
Conclusions and current suggestions 
As already highlighted by others [19, 20], a fixed waiting time before a patient 
with a previous renal cancer gets listed for renal transplantation is no longer justified, 
since it may lead to an unnecessary and harmful delay in receiving a graft.  
At present there is enough evidence that some patients may be listed immediately, 
while others are at too high a risk of metastasis to benefit from a transplanted kidney 
or improve their life expectancy, due to the prolonged immunosuppressive therapy 
needed.  
It is now clear that patients should be individually evaluated for their own risk of 
cancer recurrence after transplantation and the powerful tools presently available can 
accurately predict overall survival, cause-specific survival, or metastasis-free 
survival (in the short- and medium-term) of patients with completely resected, 
organ-confined or locally-advanced, renal cell carcinoma of all histotypes and 
specifically of papillary histotype. The main limit of these tools is that they have not 
been validated in subjects assuming immunosuppressive drugs for years, as in the 
case of transplanted patients. 
However, information is now available to help classifying some patients more 
easily.  For instance, of the several scoring systems proposed to date, the one by 
Leibovich et al. [33] is being widely used in clinical practice since it proves simple 
and reliable enough, allowing the stratification of  patients according to their risk of 
metastasis (figure 1). By this system subjects with a score from 0 to 2 are at low risk 
since more than 90% of them are metastasis-free after 10 years while, on the 
contrary, only 23% of patients with a score of 6 or higher do not have metastases 
after the same length of time. Thus, the former may be listed with a short or no 
waiting time, while the last should be excluded from a transplantation programme. 
The group of subjects with a score of 3 to 5 are at intermediate risk, 64% of them 
being metastasis-free after 10 years, thus requiring individual evaluation before 
taking a decision as to listing them or not. 
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Likewise, histological examination or tumour grading may be useful in this 
setting. As reported in table II, patients with a medullary or Bellini’s duct carcinoma 
or those with sarcomatoid de-differentiation at histology are unfit to receive a graft 
and should not be listed. Again, renal transplantation is contraindicated in subjects 
with a G4 carcinoma.  
On the other hand, patients treated for a chromophobe or clear cell papillary 
tumour or G1 carcinoma carry a low risk and may be listed.  
Unfortunately, difficulties in risk assessment still remain in all other patients, and 
they require individual and careful evaluation by an oncologist and urologist to 
decide whether they are suitable to be listed.   
Finally, given the increasing relevance of the problem, a consensus conference 
involving all specialists in the field is called for, pending studies focusing 
specifically on the risk assessment of patients with a previous renal cancer who 
become candidates for renal transplantation.  
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Table I. Waiting time recommended by current guidelines for patients with previous RCC candidates to renal transplantation 
 
Guideline [ref. #] Small (<= 4 cm) or 
incidentally discovered RCC 
Symptomatic RCC Large or invasive 
American Society of Transplantation (AST) [9] no delay 2 years contraindicated 
Core curriculum in nephrology. Evaluation of Adult 
Kidney Transplant Candidates. 2007 [10] 
no delay > 2 years 2 years 
Caring for Australasian with Renal Impairment (CARI) 
[8] 
no delay* 5 years contraindicated 
European Best Practice Guidelines (EBPG) 2000 [11] less than 2 years 2 years ? 
European Association of Urology (EAU) 2009 [12] no delay no indications no indications 
Canadian Society of Transplantation, 2005 [13] no delay 2 to 5 years 5 years 
 
* TNM staging and histological examination are recommended 
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Table II. Factors with established positive or negative prognostic value in patients 
with a previous renal cancer to be listed for kidney transplantation (see text 
for details). 
 
 
 Positive factors Negative factors 
Histology Chromophobe 
Clear cell papillary 
Medullary 
Bellini’s duct 
Sarcomatoid dedifferentiation 
Grading G1 G4 
Leibovich score 0 - 2 ≥ 6 
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 Figure 1 
 
 
 
 
 
 
 
 
Metastasis-free survival probability after renal carcinoma resection according to the 
Leibovich risk model score. Patients can be stratified into three prognostic groups at 
low, intermediate and high risk respectively.  
Modified from ref. [34] 
